T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer|Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
Interventions: DRUG: T-DM1|DRUG: Pertuzumab|PROCEDURE: Excision of tumor/mastectomy
Sponsor: Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.